The Korean Journal of Internal Medicine · 2022 · 11 citations · 23 references
MedicineImmunologyPathologyImmunopathologyInflammationPulmonologyFibrosisHypersensitivity PneumonitisInterstitial Lung DiseaseNeutrophil BiologyPulmonary InflammationPulmonary PathologyLung Function DeclineLung Function TestingLung Inflammation BiomarkersNonspecific Interstitial PneumoniaPrognostic PredictionPrognostic Prediction ModelsProgressive Pulmonary FibrosisPulmonary Fibrosis Progression
BACKGROUND/AIMS: Neutrophilia is frequently observed in bronchoalveolar lavage fluid (BALF) of idiopathic pulmonary fibrosis (IPF) patients. Granulocyte colony-stimulating factor (G-CSF) is a potent neutrophil-activating glycoprotein. However, the clinical implications of G-CSF remain poorly understood.in patients with IPF. Therefore, we evaluated the relationship between the G-CSF concentration in BALF and the progression of fibrosis, including in terms of the decline in lung function and long-term survival rate. METHODS: G-CSF concentrations were measured in BALF using enzyme-linked immunosorbent assay (ELISA). The survival rate was estimated using Kaplan-Meier survival analyses. RESULTS: G-CSF protein levels were significantly higher in IPF (n = 87; 1.88 [0 to 5.68 pg/mL]), nonspecific interstitial pneumonia (n = 22; 0.58 [0 to 11.64 pg/mL]), and hypersensitivity pneumonitis (n = 19; 2.48 [0.46 to 5.71 pg/mL]) patients than in normal controls (n = 33; 0 [0 to 0.68 pg/mL]) (all p < 0.01). A receiver operating characteristic curve showed a difference in G-CSF levels between IPF and NC (area under the curve, 0.769): The G-CSF cut-off of 0.96 pg/mL indicated 84.9% specificity and 63.2% sensitivity for IPF. The survival rate was significantly lower in the group with G-CSF > 2.872 pg/mL than in the group with ≤ 2.872 pg/mL (hazard ratio, 2.69; p = 0.041). The annual decline in diffusing capacity of the lung for carbon monoxide was positively correlated with the G-CSF level (p = 0.018). CONCLUSION: G-CSF may participate in the development of IPF and be useful for predicting the prognosis of IPF. Therefore, G-CSF should be analyzed in BALF, in addition to differential cell counts.
23
Ganesh Raghu, Harold R. Collard, Jim Egan et al. · American Journal of Respiratory and Critical Care Medicine · 2011 · 7.3K citations · Full text
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Luca Richeldi, Roland M. du Bois, Ganesh Raghu et al. · New England Journal of Medicine · 2014 · 4.6K citations · Full text
William D. Travis, Ulrich Costabel, David M. Hansell et al. · American Journal of Respiratory and Critical Care Medicine · 2013 · 4.3K citations · Full text